Biologics and Novel Therapeutics in Food Allergy
Recent Publication
A recent commentary review in The Journal of Allergy and Clinical Immunology: In Practice summarises new treatment approaches for food allergies. Co-author is Prim. Prof. Dr Thomas Eiwegger, Head of the Division of Paediatrics and Adolescent Medicine at University Hospital St. Pölten and Head of the Scientific Working Group Clinical Immunology at KL. The focus is on so-called biologics, i.e. targeted drugs that not only prevent allergic reactions, but also directly target the underlying mechanisms. The authorisation of omalizumab in the USA is considered a particularly important step: the antibody binds to IgE in the blood, a central trigger of allergic reactions, and can therefore reduce the risk of severe reactions when coming into contact with allergens.
Anderson, B., Pascal, C., Butler, M. G. K., Chin, A. R., Long, A. J., Sindher, S. B., Anagnostou, A., Arasi, S., Bégin, P., Ciaccio, C. E., Eiwegger, T., Fiocchi, A., Fleischer, D. M., Garcia-Llorett, M., Kim, E. H., Leonard, S., Maskatia, Z. R., Perrett, K. P., Shreffler, W., ... Chinthrajah, R. S. (2026). Biologics and Novel Therapeutics in Food Allergy. Journal of Allergy and Clinical Immunology: In Practice, 14(4), 762-770. https://doi.org/10.1016/j.jaip.2026.01.044
Prim. Univ.-Prof. PD Dr. Thomas Eiwegger
Scientific Working Group Clinical Immunology, Division of Paediatrics and Adolescent Medicine (University Hospital St. Pölten)